RE:Observations & Questionsconsultant99 wrote: Thanks for the feedback from those that attended the AGM. It would seem the meeting was upbeat and extremely positive - my impressions.
I was interested to see that the company's target for submitting information on the Phase 2 trial is H2 2021. I always felt that was an aggressive timeline but feel good that the company is using this as their goal.
It was good to see that the technology seems to be well understood and there is an air of acceptance that it will work. It is only a matter of time before more people become aware of the opportunity to invest; less flipping, more accumulation, increasing demand and limited supply leading to a higher share price.
Was there any discussion of patients #5 and #6 - will they continue to be monitored?
Are we dealing with a treatment that might need to be given on an ongoing basis or is this a potential cure? I for one am curious as to what becomes of the two patients that made it cancer free for a year.
From a business perspective I can figure out the potential revenues that can be generated but so far I have not heard of any estimates on the costs side. Is the chemical used expensive to manufacture? Presumably if the company can get this procedure done in a clinc rather than an OR at a hospital there could be further reductions on the cost side for the treatment.
I saw reference to a listing on NASDAQ. Obviously that would be a great get but was there any discussion about just getting a TSX listing as an interim step?
I have little fear of a share dilution to raise the funding for the phase 2 (within reason of course) but would have preffered the company look at alternatives like a 5 year convertable debenture with a reasonable interest rate attached; interest paid at maturity with conversion to shares at a some agreed to share price. CHunk it out in $5,000 increments with say a 8% coupon and conversion to common shares at $1.25/share.
What is somewhat disturbing is the admission that the company has limited resources and is therefore focusing on the bladder treatment first. If as we all believe the treatment will work and can be modified for other indications the lack of money is unnecessarily holding up the development of treatments for other indications. I applaud the company for trying to get us across the finish line for bladder cancer but can'tg help but wonder at what cost. Will shareholders be better off? Will society be better off? While I was always onside with doing it themselves I now find myself questioning that decision if it means holding up multiple future cancer treatments for years.
Maybe this is a discussion for the next AGM when any and all doubts about the outcome for the phase 2 has been put to bed and the focus is how the company will rollout the bladder cancer treatments post regulatory approval and develop the full potential for treatments of all the other cancer indications.
For now I am satisfied that the clock is ticking and there should be a parabolic rise in the share price in three years or less.
Questions were asked about the patients in phase 1.
They will continue to be followed by their uro oncologists at PMH.
TLT is not priviledged to track their personal health data ouside of the study but if they hear about their longterm follow up and have consent they will share it.
They did not comment on the costs of the drug but did mention that they have enough of it to finish phase 2. They also continue stability testing and Shawn expects that the shelf life will be fine up until 5 years (best guess). The fiberoptic and drug delivery components are disposables and likely are not outrageously expensive. Clinic use would be very beneficial as it will drive costs down and increase sales of the 3200. Kipton also had some interesting ideas on recurring revenue with the TLT 2000 following most recent upgrades (planning to build that back up again).
NIMBC is the main focus right now, and should be until the trial is up and running in at least 5-10 North American sites. Arkady mentioned that pre-clinical work continues in other indications and looks promising but they have to get NIMBC going as a priority before spreading to thin. I agree. Once we start getting an indication that the patients in phase 2 are starting to look a lot like patients #5 and 6 we are off to the races.
Look for more clinical sites to come on board over the summer across Canada and hopefully FDA submission in the next few weeks. They will also announce first patient treated at PMH.
What I observed at the meeting yesterday and from the videos is that the clinical team is on the same page as the team at TLT. This is not always the case with sponsored relationships like this. I have seen drug companies blow deals because they want to control how physician prescribe and utlize their products only to end in failed clinical trials. Looking for good things from this company, its taking a while but we will definetly get there.
Macer